Troluce Capital Advisors LLC Makes New Investment in Surgery Partners, Inc. (NASDAQ:SGRY)

Troluce Capital Advisors LLC purchased a new stake in shares of Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 409,154 shares of the company's stock, valued at approximately $8,662,000. Surgery Partners makes up about 0.3% of Troluce Capital Advisors LLC's investment portfolio, making the stock its 6th biggest position. Troluce Capital Advisors LLC owned about 0.32% of Surgery Partners as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in the business. Janus Henderson Group PLC raised its position in Surgery Partners by 110.2% in the 4th quarter. Janus Henderson Group PLC now owns 11,554,845 shares of the company's stock worth $244,616,000 after purchasing an additional 6,057,477 shares during the period. Vanguard Group Inc. grew its position in Surgery Partners by 2.3% in the 4th quarter. Vanguard Group Inc. now owns 7,618,404 shares of the company's stock valued at $161,282,000 after acquiring an additional 172,271 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in Surgery Partners by 18.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,577,861 shares of the company's stock worth $75,739,000 after purchasing an additional 563,812 shares during the period. King Street Capital Management L.P. boosted its stake in shares of Surgery Partners by 93.1% during the fourth quarter. King Street Capital Management L.P. now owns 2,800,000 shares of the company's stock valued at $59,276,000 after purchasing an additional 1,350,000 shares during the period. Finally, Point72 Asset Management L.P. increased its stake in Surgery Partners by 224.7% in the 4th quarter. Point72 Asset Management L.P. now owns 1,746,554 shares of the company's stock worth $36,975,000 after buying an additional 1,208,639 shares during the period.

Insider Transactions at Surgery Partners

In related news, insider Marissa Brittenham sold 3,156 shares of the stock in a transaction on Monday, March 10th. The shares were sold at an average price of $24.09, for a total transaction of $76,028.04. Following the sale, the insider now directly owns 63,408 shares of the company's stock, valued at approximately $1,527,498.72. This represents a 4.74% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO David T. Doherty sold 6,733 shares of Surgery Partners stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $24.02, for a total value of $161,726.66. Following the completion of the transaction, the chief financial officer now owns 150,868 shares of the company's stock, valued at approximately $3,623,849.36. This represents a 4.27% decrease in their position. The disclosure for this sale can be found here. Company insiders own 2.30% of the company's stock.

Surgery Partners Stock Up 0.9%

Shares of SGRY stock traded up $0.21 during trading hours on Friday, reaching $22.81. 188,712 shares of the company's stock were exchanged, compared to its average volume of 1,097,021. The company has a current ratio of 1.80, a quick ratio of 1.66 and a debt-to-equity ratio of 0.99. The company has a market cap of $2.92 billion, a price-to-earnings ratio of -47.39, a P/E/G ratio of 19.21 and a beta of 1.96. Surgery Partners, Inc. has a fifty-two week low of $19.50 and a fifty-two week high of $33.97. The stock's 50 day moving average is $22.49 and its 200-day moving average is $23.07.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). The company had revenue of $776.00 million for the quarter, compared to analyst estimates of $777.77 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. The business's revenue was up 8.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 EPS. Analysts predict that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently commented on SGRY shares. Macquarie reduced their target price on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating on the stock in a research report on Tuesday, March 11th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $35.00 target price on shares of Surgery Partners in a research report on Tuesday, March 25th. Finally, Benchmark reiterated a "buy" rating and issued a $35.00 target price on shares of Surgery Partners in a report on Monday, April 21st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $34.75.

Surgery Partners Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.